Placental Removal Method And Uterine Massage On Preventing Postpartum Hemorrhage
Launched by BUSRA LEKESIZ · Jan 4, 2024
Trial Information
Current as of November 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods for removing the placenta during cesarean deliveries to see which one might help prevent excessive bleeding after birth, known as postpartum hemorrhage. Researchers want to compare a technique called manual removal of the placenta with another method called controlled cord traction. They believe that while manual removal might be quicker, it could also lead to more complications, like infections and increased bleeding. Additionally, the trial will explore the effectiveness of uterine massage after cesarean delivery, a technique that has shown benefits in vaginal births but hasn’t been studied much in cesarean cases.
To participate in this trial, women must be at least 18 years old, have a single baby due at 37 weeks or later, and should not have any previous issues with uterine bleeding or other serious health problems, like gestational diabetes. Participants will undergo one of the two placenta removal methods during their cesarean delivery, and the research aims to find out which method leads to better outcomes regarding postpartum bleeding. This study is particularly important for improving maternal health, especially in areas with high rates of complications after childbirth.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Live singleton pregnancy of 37 0/7 weeks or more
- • Without history of previous uterine atony
- • No comorbidities
- • No gestational hypertension or gestational diabetes mellitus
- Exclusion Criteria:
- • In utero fetal death
- • Multiple gestation
- • History of uterine atony
- • Vaginal birth
- • Previous history of cesarean delivery
About Busra Lekesiz
Busra Lekesiz is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative clinical studies. With a focus on developing cutting-edge therapies across various therapeutic areas, Busra Lekesiz emphasizes rigorous scientific methodologies and ethical practices in all its trials. The organization collaborates with healthcare professionals, regulatory bodies, and research institutions to ensure the highest standards of safety and efficacy. By fostering an environment of transparency and collaboration, Busra Lekesiz aims to contribute significantly to the field of medicine and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Busra Lekesiz
Principal Investigator
Ankara Etlik City Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported